Coherus Oncology, Inc. (CHRS) — Financial statements
Income statement, balance sheet, and cash flow for Coherus Oncology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 42↓84.2% | 267↑3.8% | 257↑21.9% | 211↓35.4% | 327 | |
| Cost of Revenue | 18↓84.9% | 118↓26.1% | 159↑126.9% | 70↑21.7% | 58 | |
| Gross Profit | 24↓83.6% | 149↑52.1% | 98↓30.3% | 141↓47.6% | 269 | |
| Operating Expenses | ||||||
| R&D Expenses | 105↑12.5% | 93↓14.7% | 109↓45.1% | 199↓45.1% | 363 | |
| General & Administrative Expenses | 0.00↓100.0% | 140↓20.1% | 175↓7.1% | 188↑16.7% | 161 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 11↑0.0% | 11↑3.8% | 11↑20.7% | 9 | |
| SG&A Expenses | 99↓34.2% | 150↓19.0% | 186↓6.5% | 198↑17.0% | 170 | |
| Other Expenses | 0.00↓100.0% | 17↑170.3% | 6 | 0.00 | 0.00 | |
| Operating Expenses | 204↓21.9% | 261↓13.4% | 301↓24.2% | 398↓25.3% | 533 | |
| Total Costs & Expenses | 222↓41.4% | 379↓17.8% | 460↓1.6% | 468↓20.7% | 590 | |
| Operating Results | ||||||
| Operating Income | -180↓60.8% | -112↑45.0% | -203↑20.9% | -257↑2.6% | -264 | |
| Depreciation & Amortization | 4↓25.6% | 5↑39.2% | 4↑2.5% | 4↑7.1% | 3 | |
| EBITDA | -176↓388.2% | 61↑131.4% | -194↑24.1% | -256↑2.0% | -261 | |
| EBIT | -180↓422.5% | 56↑128.2% | -198↑23.7% | -259↑1.8% | -264 | |
| Interest & Other Income | ||||||
| Net Interest Income | -9↑66.9% | -27↑33.0% | -41↓24.8% | -32↓41.4% | -23 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 9↓66.9% | 27↓33.0% | 41↑24.8% | 32↑41.4% | 23 | |
| Non-Operating Income | 0.00↑100.0% | -167↓2959.6% | -5↓327.9% | 2↑748.1% | 0.28 | |
| Other Income / Expenses | -4↓102.6% | 140↑499.7% | -35↓0.6% | -35↓50.0% | -23 | |
| Income Before Tax | -183↓742.4% | 29↑112.0% | -238↑18.3% | -292↓1.6% | -287 | |
| Income Tax Expense | 0.00 | 0.00↑100.0% | -0.38 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -183↓742.4% | 29↑112.0% | -238↑18.5% | -292↓1.6% | -287 | |
| Net Income from Discontinued Operations | 13 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -170↓697.4% | 29↑112.0% | -238↑18.5% | -292↓1.6% | -287 | |
| Bottom-Line Net Income | -170↓697.4% | 29↑112.0% | -238↑18.5% | -292↓1.6% | -287 | |
| EPS (Basic) | -1.45↓680.0% | 0.25↑109.9% | -2.53↑32.7% | -3.76↑1.3% | -3.81 | |
| EPS (Diluted) | -1.45↓680.0% | 0.25↑109.9% | -2.53↑32.7% | -3.76↑1.3% | -3.81 | |
| Weighted Average Shares | 120↑5.1% | 115↑21.7% | 94↑21.3% | 78↑2.9% | 75 | |
| Weighted Average Diluted Shares | 120↑4.8% | 115↑21.9% | 94↑21.3% | 78↑2.9% | 75 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.